Boehringer Ingelheim Press Releases

Boehringer Ingelheim submits first oncology compound, afatinib* for European approval

Boehringer Ingelheim launches beta social game Syrum to promote science and innovation

Asian populations with atrial fibrillation (AF) benefit from better stroke prevention with Pradaxa® (dabigatran etexilate) compared to warfarin

Boehringer Ingelheim implements flexible fully disposable up- and downstream manufacturing for biopharmaceuticals

Boehringer Ingelheim and the ETH Zurich announce diabetes and obesity research collaboration

SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD

New data show significant improvements in lung function using combination of tiotropium and olodaterol* in COPD patients

Phase III results: tiotropium* Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment

New bottle for Ingelvac MycoFLEX® simplifies mixing with Ingelvac CircoFLEX®

Large scale registry shows atrial fibrillation management is suboptimal and unequal around the world

Key results from new tiotropium studies in COPD and asthma
to be presented at ERS 2012

Clinical experience with Pradaxa® crosses one million patient-years of treatment

Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed

Boehringer Ingelheim achieves further growth in first half of 2012 – difficult business environment expected for the second half of the year

Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier

Jentadueto® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe

Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

Ilka Diester wins Boehringer Ingelheim’s FENS Award 2012 for Exceptional Research in Neuroscience